
Health changes everything: Europe’s smart investment
Europe’s ageing populations and rising chronic disease threaten to sap growth. Treating health care as an investment, not a cost, could prove the continent’s smartest economic strategy


By Kris Sterkens, Company Group Chairman at Johnson & Johnson Innovative Medicine (EMEA)
By the middle of this century, nearly one in three Europeans will be over 65. Chronic disease is rising and the working-age population is shrinking, however health care spending is not keeping pace with these evolving demographics and increasing demands.
Across the continent, governments have balanced budgets by trimming the very investment that keeps economies functioning. Confronted with ageing populations and mounting disease, Europe faces a defining question: is health spending an expense to contain—or an investment in productivity and growth?
While austerity measures may have a short term impact, evidence shows that for every €1 Europe invests in health, it receives more than double back in economic benefits in addition to direct health improvements. When health is treated as an economic asset rather than a fiscal burden, it becomes a driver of growth, competitiveness and prosperity.
The false economy of austerity
Health care cost-containment policies introduced after the 2008 financial crisis balanced budgets but weakened health systems. Hospital capacity fell, innovation in treatment reduced pace in Europe relative to China and the USA, and access to medicines slowed for years in some of Europe's poorest countries.
These policies have reduced Europe's preparedness for demographic and health challenges and increased its vulnerability to a decline in competitiveness. As former European Central Bank President Mario Draghi noted in his report on EU competitiveness, Europe’s growth potential now depends on investing in productivity, innovation and human capital. Health care sits at the intersection of all three. Cutting it may shrink deficits briefly, but it erodes the foundations of economic and social strength for years to come. Political decision-makers should think beyond electoral cycles and focus on health outcomes across lifetimes, not just budget years.

While several countries are waking up to the wider economic benefits of investing in health care, the inclination to view health as an expense still dominates, crowding out investment in innovation across Europe.
Germany’s new coalition government has recognised health care as an industrial sector vital to growth and pledged reforms to strengthen it. But, over recent years, the dilution of Germany’s once-reliable value-based system risks eroding the very innovation it was designed to recognise. This unpredictability jeopardises the industry's investments and patients’ access to innovations.
In England, the National Health Service (NHS) has launched its 10 Year Health Plan with a focus on early disease prevention—saving lives and resources. Yet treatment for patients already in the system remains inadequate. Only 65% of new therapies approved in Europe currently reach NHS patients and Britain has been spending less on medicines than almost any other comparable country. This, coupled with an unpredictable and unsustainable clawback mechanism has, to date, made the UK a major outlier. This situation has been acknowledged by the UK government marking a first step in the right direction.
France’s Stratégie Nationale de santé 2023-2033 promotes collaboration, equity, prevention and adaptation to local realities. In parallel, the drive to contain costs has hardened into a systemic constraint. A draft social security bill could pile further taxes on the pharmaceutical sector, adversely impacting innovation as a result. This comes on top of the existing threat to the French early-access schemes that once made the country a model for rapid patient access. Italy provides universal health coverage, strong primary care and recognises the importance of pharmaceutical innovation. A newly proposed Italian law aims to harmonise regulation, pricing, reimbursement and market access that would streamline governance and further promote innovation. However, an unpredictable payback system (over €2 billion in 2024) undermines pharmaceutical investment and regional fragmentation delays access to new therapies.
Across many Central and Eastern European countries, patients continue to wait longer than those in Western Europe for new treatments. Progress has been made, notably in Poland, but a gap still exists.
“Prevent what you can, treat what you can’t—and invest in both.”
Health as Europe’s smartest economic strategy
A new realism would treat health care as an investment in growth, not a social luxury, and there are glimmers of hope.
While some governments are starting to see that investment in prevention, innovation and resilience yields long-term economic dividends, further action is needed. This means incentivising early action on chronic diseases, supporting research-based health care industries and building data systems that enable smarter, more equitable access to care. The goal should be to prevent what you can, treat what you can’t—and invest in both. It’s not about spending indiscriminately, but spending intelligently, recognising that investment in health care underpins every other pillar of economic competitiveness.
“Europe’s competitiveness tomorrow depends on the health of its people today.”
Europe’s competitiveness tomorrow depends on the health of its people today. When governments prioritise health, people’s lives improve, communities prosper and economies grow stronger.
Health changes everything.
CP-556762 | December 2025